Clinical trial
TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine…
NCT00023387 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00023387 |
|---|---|
| Title | TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine |
| Official title | Intensive Pharmacokinetic Study of Three Doses of Rifapentine (600, 900 and 1200mg) During Continuation Phase Therapy of Tuberculosis in HIV-Negative Adults |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | US Department of Veterans Affairs U.S. Fed |
| Status | Completed |
| Study type | Interventional |
| Conditions | Tuberculosis |
| Intervention type | Drug |
| Interventions | Rifapentine, 25-desacetyl Rifapentine, Isoniazid |
| Enrollment | 36 |
| Start date | Mar 1, 2000 |
| Completion | May 1, 2001 |
| First posted | Sep 10, 2001 |
| Last update posted | Sep 13, 2005 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: